Apexigen™ is a biopharmaceutical product development company pioneering the next generation of antibody drugs. With the use of proprietary platform technology based on humanized rabbit-derived antibodies, the company seeks to aid in the discovery and development of better treatments for serious and difficult-to-treat diseases. The company was acquired by Pyxis Oncology in August 2023.